lab microscope analyzing chemosensitivity test.jpg

Published Papers

Since founding Rational Therapeutics over 20 years ago, Dr. Nagourney, his team and colleagues have published a number of papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death functional profiling assay, as well as effectiveness of new drugs and combinations.     How We Test Your Cancer Infographic

We have selected a few of our most prominent papers to make available for download on this site. If you would like copies of any papers not listed below, please contact our office at 800-542-4357.

Accuracy and clinical utility of in vitro cytometric profiling to personalize chemotherapy: Preliminary findings of a systematic review and meta-analysis. J Clin Oncol 31, 2013 (suppl: abst e22188).

A meta-analysis of 2,581 patient outcomes reported at ASCO (American Society of Clinical Oncology) 2013, confirmed the capacity of these platforms to more than double (2.04-fold 95% CI 1.62-2.57, P < 0.001) clinical response to chemotherapy and to improve one-year survival by 1.4 fold.  

 

A meta-analysis reported at the 2007 ASH annual meeting of 1,929 hematologic malignancies provided a 2.48 fold improvement (2.48 (95% CI, 2.15-2.87) in response rate utilizing assay sensitive drugs.  

 

Cost benefit analysis of laboratory directed chemotherapy for advanced pancreatic cancer in US and Brazilian patients (ASCO 2013) reveals clinically validated drug selection methods can provide superior response rates in advanced pancreatic cancer at comparable or lower costs per response.  J Clin Oncol 33, 2015 (abst e17782).

Functional Profiling to Select Chemotherapy in Untreated, Advanced or Metastatic Non-small Cell Lung Cancer. Robert A. Nagourney, Jonathan B. Blitzer, Robert L. Shuman, Thomas J. Asciuto, Eknath A. Deo, Marylyn Paulsen, Robert L. Newcomb and Steve S. Evans. Anticancer Research 32:4453-4460 (2012).

Metastatic lung cancer patients receive treatments chosen by the EVA-PCD functional profile and obtain a two-fold improvement in response to treatment and survival.  A Phase II study published in the October 2012 issue of Anticancer Research.

Cisplatin Plus Gemcitabine in Previously Treated Squamous Cell Carcinoma of the Cervix: A stage II study of the Gynecologic Oncology Group (2005) Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, D. Scott McMeekin, Shashikant Lele, and Susan L. Zweizig. Gynecol Oncol. 100(2):385-8, Feb 2006

This study suggests modest activity for the gemcitabine plus cisplatin doublet in previously treated squamous call carcinoma of the cervix. The objective response of 22 percent is comparable to that of other active agents and combinations tested in this setting. Toxicities were primarily hematologic and generally manageable with dose reductions. 

Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients (2000) By Robert A. Nagourney, John S. Link, Jonathan B. Blitzer, Cynthia Forsthoff, and Steven S. Evans. J Clin Oncol. Vol 18, Issue 11, 2000:2245-2249

Cisplatin plus gemcitabine is active and tolerable for patients with relapsed breast cancer. Responses observed in previously treated patients, including high-dose/stem-cell failures, indicate activity in otherwise drug-refractory (resistant) patients.

Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients (2002) Robert A. Nagourney, MD; Cheryl A. Brewer, MD; Stephen Radecki, PhD; Wesley A. Kidder; Barbara L. Sommers, RN; Steven S. Evans, MA; David R. Minor, MD; and Philip J. DiSaia, MD. Gynecol Oncol. 88, 35-39 (2003)

Cisplatin plus gemcitabine is active for patients with relapsed ovarian cancer. Toxicities, primarily hematologic, are manageable with dose modifications. Responses observed in heavily pretreated and platin-resistant patients indicate activity in drug-refractory patients. The results of the Ex Vivo Analyses correlate with clinical outcomes.

Ex-Vivo Programmed Cell Death and the Prediction of Response to Chemotherapy (2006) Robert A. Nagourney, MD. Current Treatment Options in Oncology, Vol 7, issue 2, March 2006.

Carboplatin plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer (2008) Robert A. Nagourney, Marshall Flam, John Link, Steven Hager, Jonathan Blitzer, William Lyons, Barbara L. Sommers, and Steven Evans. Clin Breast Cancer, Oct 2008

The repeating doublet of split-dose carboplatin plus gemcitabine reveals activity comparable to that of cisplatin plus gemcitabine, is well tolerated and warrants evaluation in patients with recurrent breast cancer.

The Once and Future Role of the Platinum Agents in Advanced Breast Cancer (2000) Robert A. Nagourney, MD. Clin Breast Ca Vol 5; No 2:123-124, 2000. Nagourney RA: Letter to the Editor. Gynecol Oncol. 76(1):143, 2000

As the platinum agents gain popularity in the management of breast cancer, this important class of drugs has the potential to improve outcome for one of the most common human malignancies.

Cisplatin plus Gemcitabine in Platinum-refractory Ovarian or Primary Peritoneal Cancer: A Phase II Study of the Gynecologic Oncology Group (2006) Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, Mark Morgan, Parviz Hanjani. Gynecol Oncol. 2006 Apr 24

Cisplatin plus gemcitabine, in the doses and schedule employed, has modest activity in this patient population.

An RNAi-based Chemical Genetic Screen Identifies Three Small-molecule Inhibitors of the Wnt/wingless Signaling Pathway. Foster C. Gonsalves, Karen Klein, Brittany B. Carson, Shauna Katz, Laura A. Ekas, Steve Evans, Robert Nagourney, Timothy Cardoza, Anthony M. C. Brown, and Ramanju DasGupta. PNAS Vol 108; No15:5954-5963 Apr 2011.

The WNT pathway was originally described in fruit flies as a determinate of wing shape. It was subsequently shown to be an important factor in human stem cell differentiation. Recognizing the importance of this pathway, the investigators at NYU and Cornell used a technology known as small interfering RNA (SIRNA) to shut down the WNT signal. They then screened 14,000 know chemicals for activity that mimicked the SIRNA effect. Three compounds were identified.  

Back to Top